Skip to main content

Table 3 Comparison between patients’ characteristics, consanguinity and family history rate of the three groups

From: The expanded clinical profile and the efficacy of colchicine therapy in Egyptian children suffering from familial mediterranean fever: a descriptive study

Item Heterozygous (n=40) Homozygous (n=20) Gene-ve (n=10) P-value
Age of onset (yeas), mean ± SD 5.20 ± 2.51 4.32 ± 2.58 4.63 ± 2.76 0.35
Age at diagnosis (years), mean ± SD 7.81 ± 2.79 6.01 ± 2.75 6.76 ± 3.08 0.07
Time interval between disease onset and diagnosis (years)     
Mean ± SD 2.63 ± 1.63 1.75 ± 1.03 2.15 ± 1.94 0.13
Median (range) 2 (1–6) 1.8 (1–4) 1.3 (1–7)  
Duration of follow-up (years), mean ± SD 2.18 ± 1.41 3.80 ± 3.24 2.95 ± 2.77 0.11
Median (range) 1.75 (1–6) 2 (1–11) 1.95 (1 – 9)  
Male/Female 21/19 12/8 7/3 0.58
Consanguinity (n%) 14 (35%) 11 (55%) 1 (10%) 0.05
Family history of FMF (n%) 7 (17.5%) 7 (35%) 0 (0%) 0.06
Family history of amyloidosis (n%) 4 (10%) 0 (0%) 0 (0%) 0.20
  1. FMF= familial Mediterranean fever.
  2. *P-value less than 0.05 is considered statistically significant.